Asthma Insurance Claim Denied in Maryland? MIA and Maryland Health Exchange Appeal Rights

Maryland's Chesapeake Bay geography, urban pollution in Baltimore, and industrial legacy in communities along the Baltimore Harbor make asthma and COPD medically significant conditions across the state. If your Maryland insurer has denied biologics or specialist care, the Maryland Insurance Administration and HealthChoice Medicaid give you meaningful rights to appeal.

Why Maryland Insurers Deny Asthma Claims

Common denial patterns in Maryland:

• Step therapy for biologics: Requiring failure on controller medications before approving Dupixent, Fasenra, Nucala, or Tezspire
• COPD biologic denials: Denying Nucala for COPD despite FDA approval, citing "asthma-only" formulary restrictions
• Prior Authorization Denied: How to Appeal" class="auto-link">Prior authorization for nebulizers: Home nebulizers denied as duplicative with inhaler therapy
• Rescue inhaler quantity restrictions: Albuterol limits even for patients with frequent exacerbations
• Out-of-network specialist denials: Western Maryland and Eastern Shore patients often lack in-network allergists and pulmonologists
• HealthChoice MCO barriers: Maryland Medicaid managed care organizations apply restrictive prior authorization criteria

Maryland Insurance Regulator: MIA

The Maryland Insurance Administration (MIA) regulates health insurers in Maryland.

MIA Consumer Services:

• Phone: 1-410-468-2000
• Toll-free: 1-800-492-6116
• Website: insurance.maryland.gov
• File a complaint: insurance.maryland.gov/Consumer/Pages/home.aspx

Maryland law provides for External Independent Review: Complete Guide" class="auto-link">external review of adverse benefit determinations by certified IROs. External review decisions are binding on the insurer. Standard reviews are completed within 45 days; expedited reviews within 72 hours.

Maryland Health Exchange Marketplace Plans

The Maryland Health Connection (marylandhealthconnection.gov) is Maryland's ACA marketplace. Plans sold through the Maryland Health Exchange are subject to full MIA oversight and Maryland's external review laws. Maryland has been expanding marketplace options and offers a public option-style plan called Maryland Easy Enrollment for certain populations.

Maryland's step therapy reform law requires insurers to grant step therapy exceptions when:

• The required medication is contraindicated
• The patient previously failed the required medication
• The step therapy requirement would cause clinically significant harm

Insurers must respond to step therapy exception requests within 72 hours (standard) or 24 hours (urgent).

HealthChoice: Maryland's Medicaid Managed Care

Maryland's Medicaid program is called HealthChoice, delivered through MCOs including Aetna Better Health of Maryland, Amerigroup Maryland, CareFirst Community Health Plan, Jai Medical Systems, Kaiser Permanente Mid-Atlantic, Maryland Physicians Care, Priority Partners (Johns Hopkins/JHHC), and University of Maryland Health Partners.

For HealthChoice MCO denials:

• File a grievance with your MCO within 90 days of denial
• Request a State Fair Hearing through the Maryland Office of Administrative Hearings: 1-410-764-3784
• Contact Maryland Volunteer Lawyers Service: mvls.org for free legal help
• Contact Legal Aid Bureau: mdlab.org — statewide free legal services
• Aid Continuing: HealthChoice members may be able to continue treatment during an appeal — ask your MCO

Baltimore Asthma Disparities

Baltimore City has some of Maryland's highest asthma rates, concentrated in East Baltimore, West Baltimore, and neighborhoods near the Port of Baltimore and Baltimore Harbor. Diesel truck traffic from port operations, industrial facilities in Dundalk and Sparrows Point, and aging housing stock with lead paint, cockroach allergens, and mold create significant environmental asthma burdens.

The NAACP Baltimore City Branch (naacpbaltimore.org) and the Baltimore City Health Department's Asthma program (health.baltimorecity.gov) document health disparities in affected communities. The University of Maryland Center for Health Equity and Johns Hopkins's public health programs have published extensively on Baltimore asthma disparities. This published research can be cited in your medical necessity argument.

COPD Biologic Appeals: Nucala's Maryland Opportunity

For Maryland COPD patients, Nucala (mepolizumab) FDA approval for COPD with eosinophilic phenotype (2023) is particularly relevant. Maryland has legacy industrial workers from Bethlehem Steel's Sparrows Point facility, Lockheed Martin manufacturing, and Harford and Baltimore County industrial operations who may have occupational COPD with eosinophilic phenotype.

If your Maryland insurer denies Nucala for COPD:

• Document COPD diagnosis with spirometry (FEV1/FVC < 0.70 post-bronchodilator), eosinophil level ≥300 cells/μL, and exacerbation history
• Cite the FDA COPD indication explicitly in your appeal letter
• Request MIA external review if internal appeal fails

FDA-Approved Biologics: Building Your Maryland Appeal

• Dupixent (dupilumab): Moderate-to-severe eosinophilic or OCS-dependent asthma; also eczema and nasal polyps
• Fasenra (benralizumab): Severe eosinophilic asthma
• Nucala (mepolizumab): Severe eosinophilic asthma; COPD with eosinophilic phenotype
• Tezspire (tezepelumab): Uncontrolled severe asthma — no eosinophil minimum; appropriate for Baltimore patients with complex multi-trigger asthma
• Xolair (omalizumab): Moderate-to-severe allergic asthma with IgE sensitization — Maryland's Chesapeake Bay region allergen environment (tree pollen, grass pollen, mold) makes allergic asthma common

Documentation: eosinophil counts, IgE levels, spirometry, exacerbation and hospitalization history, prior medication trials with outcomes, and any occupational or environmental exposure documentation.

Step-by-Step Appeal Process in Maryland

1. Get denial in writing: Full EOB and denial letter with specific clinical criteria
2. Internal appeal: File within 60–180 days; include physician letter, lab values, environmental exposure documentation
3. Peer-to-peer review: Physician contacts insurer's medical director
4. Step therapy exception: Formal request citing Maryland step therapy law
5. MIA external review: After internal appeal exhaustion; binding on insurer
6. MIA complaint: insurance.maryland.gov — complaints are investigated

Maryland Advocacy Resources

• American Lung Association – Maryland: lung.org | 1-800-586-4872
• Maryland Volunteer Lawyers Service: mvls.org — free legal help including insurance appeals
• Legal Aid Bureau: mdlab.org — statewide free legal services
• Chesapeake Climate Action Network: chesapeakeclimate.org — environmental health resources
• NAACP Maryland State Conference: marylandnaacp.org — health equity advocacy

Fight Back With ClaimBack

From Baltimore's Harbor Point to Western Maryland's rural communities, asthma patients deserve the treatments their physicians prescribe. ClaimBack builds professional Maryland-specific appeal letters that invoke your rights under MIA oversight and Maryland's step therapy reform law.

Start your appeal at ClaimBack — your doctor's recommendation deserves to be honored.

Related Reading:

• How to Write an Insurance Appeal Letter
• Internal vs. External Insurance Appeal: Which Should You File?
• Common Reasons Insurance Claims Are Denied